90 related articles for article (PubMed ID: 12820323)
21. Serum levels of interleukin-6 in patients with primary head and neck squamous cell carcinoma.
Riedel F; Zaiss I; Herzog D; Götte K; Naim R; Hörmann K
Anticancer Res; 2005; 25(4):2761-5. PubMed ID: 16080523
[TBL] [Abstract][Full Text] [Related]
22. Serum CYFRA 21-1 in patients with invasive bladder cancer and its relevance as a tumor marker during chemotherapy.
Andreadis C; Touloupidis S; Galaktidou G; Kortsaris AH; Boutis A; Mouratidou D
J Urol; 2005 Nov; 174(5):1771-5; discussion 1775-6. PubMed ID: 16217281
[TBL] [Abstract][Full Text] [Related]
23. CYFRA 21-1: a suitable tumor marker in patients with head and neck cutaneous squamous cell carcinoma?
Rudhart SA; Schultz JD; Gehrt F; Pavel FL; Birk R; Hoch M; Stuck BA; Hoch S
Eur Arch Otorhinolaryngol; 2019 Dec; 276(12):3467-3475. PubMed ID: 31482332
[TBL] [Abstract][Full Text] [Related]
24. Clinical effectiveness of tumor markers in squamous cell carcinoma of the larynx.
Eleftheriadou A; Chalastras T; Ferekidou E; Kyriou L; Yiotakis I; Pappas Z; Ferekidis E; Kandiloros D
Anticancer Res; 2006; 26(3B):2493-7. PubMed ID: 16821638
[TBL] [Abstract][Full Text] [Related]
25. CYFRA 21-1 and CEA are independent prognostic factors in 153 operated stage I NSCLC patients.
Muley T; Dienemann H; Ebert W
Anticancer Res; 2004; 24(3b):1953-6. PubMed ID: 15274383
[TBL] [Abstract][Full Text] [Related]
26. Clinical evaluation of a new molecular method for detection of micrometastases in head and neck squamous cell carcinoma.
Shores CG; Yin X; Funkhouser W; Yarbrough W
Arch Otolaryngol Head Neck Surg; 2004 Aug; 130(8):937-42. PubMed ID: 15313863
[TBL] [Abstract][Full Text] [Related]
27. Role of nitric oxide in the development of distant metastasis from squamous cell carcinoma.
Scher RL
Laryngoscope; 2007 Feb; 117(2):199-209. PubMed ID: 17277613
[TBL] [Abstract][Full Text] [Related]
28. Prospective validation of serum CYFRA 21-1, beta-2-microglobulin, and ferritin levels as prognostic markers in patients with nonmetastatic nasopharyngeal carcinoma undergoing radiotherapy.
Ma BB; Leungm SF; Hui EP; Mo F; Kwan WH; Zee B; Yuen J; Chan AT
Cancer; 2004 Aug; 101(4):776-81. PubMed ID: 15305409
[TBL] [Abstract][Full Text] [Related]
29. Increased CYFRA 21-1 and CEA levels are negative predictors of outcome in p-stage I NSCLC.
Muley T; Dienemann H; Ebert W
Anticancer Res; 2003; 23(5b):4085-93. PubMed ID: 14666606
[TBL] [Abstract][Full Text] [Related]
30. Preoperative CYFRA 21-1 levels as a prognostic factor in c-stage I non-small cell lung cancer.
Suzuki H; Ishikawa S; Satoh H; Ishikawa H; Sakai M; Yamamoto T; Onizuka M; Sakakibara Y
Eur J Cardiothorac Surg; 2007 Oct; 32(4):648-52. PubMed ID: 17707649
[TBL] [Abstract][Full Text] [Related]
31. Prediction of distant metastasis in head neck cancer patients: implications for induction chemotherapy and pre-treatment staging?
Studer G; Seifert B; Glanzmann C
Strahlenther Onkol; 2008 Nov; 184(11):580-5. PubMed ID: 19016016
[TBL] [Abstract][Full Text] [Related]
32. Utility of 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography and positron emission tomography/computed tomography imaging in the preoperative staging of head and neck squamous cell carcinoma.
Roh JL; Yeo NK; Kim JS; Lee JH; Cho KJ; Choi SH; Nam SY; Kim SY
Oral Oncol; 2007 Oct; 43(9):887-93. PubMed ID: 17207656
[TBL] [Abstract][Full Text] [Related]
33. Salivary soluble CD44: a potential molecular marker for head and neck cancer.
Franzmann EJ; Reategui EP; Carraway KL; Hamilton KL; Weed DT; Goodwin WJ
Cancer Epidemiol Biomarkers Prev; 2005 Mar; 14(3):735-9. PubMed ID: 15767360
[TBL] [Abstract][Full Text] [Related]
34. Expression of CXCR4 and its down-regulation by IFN-gamma in head and neck squamous cell carcinoma.
Katayama A; Ogino T; Bandoh N; Nonaka S; Harabuchi Y
Clin Cancer Res; 2005 Apr; 11(8):2937-46. PubMed ID: 15837745
[TBL] [Abstract][Full Text] [Related]
35. CYFRA 21-1 in non-small cell lung cancer--standardisation and application during diagnosis.
Pavićević R; Bubanović G; Franjević A; Stancić-Rokotov D; Samarzija M
Coll Antropol; 2008 Jun; 32(2):485-98. PubMed ID: 18756899
[TBL] [Abstract][Full Text] [Related]
36. Analytical and clinical evaluation of CYFRA 21-1 by electrochemiluminescent immunoassay in head and neck squamous cell carcinoma.
Kuropkat C; Werner JA
J Laryngol Otol; 2003 Dec; 117(12):1007-8; author reply 1008-9. PubMed ID: 14738621
[No Abstract] [Full Text] [Related]
37. The association between elevated EphB4 expression, smoking status, and advanced-stage disease in patients with head and neck squamous cell carcinoma.
Sinha UK; Mazhar K; Chinn SB; Dhillon VK; Liu L; Masood R; Rice DH; Gill PS
Arch Otolaryngol Head Neck Surg; 2006 Oct; 132(10):1053-9. PubMed ID: 17043250
[TBL] [Abstract][Full Text] [Related]
38. Management of the unknown primary carcinoma: long-term follow-up on a negative PET scan and negative panendoscopy.
Miller FR; Karnad AB; Eng T; Hussey DH; Stan McGuff H; Otto RA
Head Neck; 2008 Jan; 30(1):28-34. PubMed ID: 17657782
[TBL] [Abstract][Full Text] [Related]
39. Identification of distant metastases with positron-emission tomography-computed tomography in patients with previously untreated head and neck cancer.
Gourin CG; Watts TL; Williams HT; Patel VS; Bilodeau PA; Coleman TA
Laryngoscope; 2008 Apr; 118(4):671-5. PubMed ID: 18197136
[TBL] [Abstract][Full Text] [Related]
40. The serum assay of tumour markers in the prognostic evaluation, treatment monitoring and follow-up of patients with cervical cancer: a review of the literature.
Gadducci A; Tana R; Cosio S; Genazzani AR
Crit Rev Oncol Hematol; 2008 Apr; 66(1):10-20. PubMed ID: 17964182
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
